Morphosys AG O.N. (MORG)

32.315
-0.795(-2.40%)
  • Volume:
    426,454
  • Bid/Ask:
    32.290/32.340
  • Day's Range:
    31.560 - 33.400
  • Type:Equity
  • Market:Germany
  • ISIN:DE0006632003
  • WKN:663200

MORG Overview

Prev. Close
32.315
Day's Range
31.56-33.4
Revenue
162.7M
Open
33.4
52 wk Range
31.56-101.9
EPS
-3.18
Volume
426,454
Market Cap
1.1B
Dividend (Yield)
N/A
(N/A)
Average Volume (3m)
312,594
P/E Ratio
-
Beta
0.74
1-Year Change
-64.69%
Shares Outstanding
34,141,025
Next Earnings Date
15 Mar 2022
What is your sentiment on Morphosys AG O.N.?
or
Market is currently closed. Voting is open during market hours.

  • Morphosys AG Earnings, Revenue miss in Q3
    • ByInvesting.com-

    Investing.com - Morphosys AG reported on Wednesday third quarter earnings that missed analysts' forecasts and revenue that fell short of expectations. Morphosys AG announced...

  • Morphosys AG Earnings, Revenue beat in Q2
    • ByInvesting.com-

    Investing.com - Morphosys AG reported on Wednesday second quarter earnings that beat analysts' forecasts and revenue that topped expectations. Morphosys AG announced earnings per...

  • Morphosys AG Earnings miss, Revenue beats In Q1
    • ByInvesting.com-

    Investing.com - Morphosys AG reported on Wednesday first quarter earnings that missed analysts' forecasts and revenue that topped expectations. Morphosys AG announced earnings...

Morphosys AG O.N. Company Profile

Employees
607
Market
Germany

MorphoSys AG, together with its subsidiaries, discovers, develops and commercializes therapeutic antibodies for patients suffering from cancer and autoimmune diseases in the United States. Its lead product candidate is Tafasitamab, an antibody for the treatment of B cell malignancies, including diffuse large B cell lymphoma and chronic lymphocytic leukemia. The company develops Tremfya, an antibody to treat plaque psoriasis, psoriatic arthritis, Crohn’s disease, ulcerative colitis, hidradenitis suppurativa, and adenomatous polyposis diseases; Gantenerumab, an antibody for the treatment of Alzheimer’s diseases through its pharmaceutical partners; Otilimab, an antibody for rheumatoid arthritis; and MOR106, an antibody for atopic dermatitis. It also develops Felzartamab, an antibody directed against CD38, which is in Phase I/II clinical trials for the treatment of anti-PLA2R-positive membranous nephropathy, an autoimmune disease. MorphoSys AG has a regional licensing agreement with I-Mab Biopharma to develop and commercialize felzartamab in China, Taiwan, Hong Kong, and Macau; a strategic alliance with the LEO Pharma; a joint collaboration and license agreement with Incyte Corporation for the development and commercialization of MorphoSys investigational compound tafasitamab (MOR208); and a clinical collaboration with Incyte Corporation and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was founded in 1992 and is headquartered in Planegg, Germany.

Read More

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesSellSellSellStrong SellStrong Sell
Technical IndicatorsStrong SellNeutralStrong SellStrong SellStrong Sell
SummaryStrong SellNeutralStrong SellStrong SellStrong Sell
    Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
    Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.